-+ 0.00%
-+ 0.00%
-+ 0.00%

Genmab To Present 14 Abstracts Evaluating Epcoritamab As Monotherapy And In Combination Across Disease Settings In Patients With DLBCL And FL At EHA Congress 2025

Benzinga·05/14/2025 14:17:09
Listen to the news
  • Data from 14 abstracts highlight the depth, breadth, and strength of Genmab's comprehensive epcoritamab development program across multiple patient populations and treatment settings

Genmab A/S (NASDAQ:GMAB) announced today that it will present 14 abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy and in combination across disease settings in patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) at the 30th European Hematology Association (EHA) Congress, being held in Milan, Italy, and virtually, June 12-15, 2025.

Two oral presentations will feature data from the Phase 1/2 EPCORE® NHL-2 trial evaluating epcoritamab plus rituximab and ifosfamide-carboplatin-etoposide (R-ICE) in patients with relapsed/refractory (R/R) DLBCL eligible for autologous stem cell transplantation, and the Phase 1/2 EPCORE NHL-5 trial evaluating epcoritamab plus polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) in previously-untreated patients with DLBCL. Additionally, results from the Phase 1/2 EPCORE NHL-1 and NHL-3 trials, including three years of follow-up in patients with R/R DLBCL and FL treated with epcoritamab monotherapy, will be presented as a poster.